Alkermes, Inc. ALKS today announced positive topline results from a
phase 1b, double-blind, randomized, placebo-controlled study of ALKS 9070 in
patients with schizophrenia. ALKS 9070, a proprietary Alkermes molecule for
the treatment of schizophrenia, is designed to provide patients with
once-monthly dosing of a medication that, once in the body, converts into
aripiprazole, a molecule that is commercially available under the name
ABILIFY for the treatment of a number of central nervous system disorders.
Data from the study showed that ALKS 9070 was generally well
tolerated, achieved therapeutically relevant plasma concentrations of
aripiprazole with a pharmacokinetic profile that supports once-monthly dosing.
Based on these results, Alkermes plans to advance ALKS 9070 into pivotal
development by the end of calendar 2011.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in